For instance, simvastatin, across a large dose range (2–60 mg/kg), inhibited the progression of experimental AAAs created by intra-aortic elastase infusion, subcutaneous Ang II infusion, or abluminal peri-aortic calcium chloride application without apparent influence on serum cholesterol concentrations [10,11,20,27,28,29]. Here, AGT is linked to achalasia-alacrima syndrome.